{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T18:09:26Z","timestamp":1788199766262,"version":"build-2803163510"},"reference-count":159,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Diabetes mellitus, particularly type 2 diabetes mellitus (T2DM), represents a rapidly expanding global health challenge with substantial public health and economic consequences. Recent advances in antidiabetic therapy\u2014including dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), dual GIP\/GLP-1 receptor agonists, and sodium\u2013glucose cotransporter-2 (SGLT-2) inhibitors\u2014have transformed diabetes management by providing benefits beyond glycemic control, such as cardiovascular and renal protection, weight reduction, and improved quality of life. As the therapeutic landscape becomes increasingly complex and patient-centered, ensuring the safe and effective use of these agents in real-world settings has emerged as a key concern for pharmacoepidemiology and pharmacovigilance. Community pharmacists, as highly accessible healthcare professionals, play an expanding role in diabetes care through medication optimization, patient education, adherence support, and monitoring of adverse drug reactions in primary care. Evidence from systematic reviews and meta-analyses indicates that pharmacist-led interventions improve glycemic outcomes, enhance self-care behaviors, and facilitate the appropriate adoption of contemporary antidiabetic therapies. This narrative review synthesizes current evidence on novel pharmacological treatments for T2DM and examines the evolving contribution of community pharmacists in translating therapeutic innovation into routine practice. Barriers to implementation and future perspectives for integrating pharmacist-led services into diabetes management and pharmacovigilance frameworks are also discussed.<\/jats:p>","DOI":"10.3390\/ph19020271","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T15:24:19Z","timestamp":1770305059000},"page":"271","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Bridging Innovation and Practice in Type 2 Diabetes Mellitus: Novel Antidiabetic Therapies and the Expanding Role of Community Pharmacists"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2163-0653","authenticated-orcid":false,"given":"Marios","family":"Spanakis","sequence":"first","affiliation":[{"name":"Department of Social Medicine, School of Medicine, University of Crete, 70013 Heraklion, Greece"},{"name":"Community Pharmacists Association of Heraklion, 71201 Heraklion, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agapi","family":"Fournaraki","sequence":"additional","affiliation":[{"name":"Community Pharmacists Association of Rethymno, 74132 Rethymno, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0990-3874","authenticated-orcid":false,"given":"Frantzeska","family":"Nimee","sequence":"additional","affiliation":[{"name":"Laboratory of Hygiene and Environmental Protection, Department of Medicine, Democritus University of Thrace, 68100 Alexandroupolis, Greece"},{"name":"Community Pharmacists Association of Athens, 10436 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7835-8246","authenticated-orcid":false,"given":"Christos","family":"Kontogiorgis","sequence":"additional","affiliation":[{"name":"Laboratory of Hygiene and Environmental Protection, Department of Medicine, Democritus University of Thrace, 68100 Alexandroupolis, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanouil K.","family":"Symvoulakis","sequence":"additional","affiliation":[{"name":"Department of Social Medicine, School of Medicine, University of Crete, 70013 Heraklion, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"155332","DOI":"10.1016\/j.metabol.2022.155332","article-title":"Pharmacotherapy of Type 2 Diabetes: An Update and Future Directions","volume":"137","author":"DeMarsilis","year":"2022","journal-title":"Metabolism"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Teng, Y., Fan, X., Yu, R., and Yang, X. (2024). Evaluation and Comparison of Efficacy and Safety of Tirzepatide, Liraglutide and SGLT2i in Patients with Type 2 Diabetes Mellitus: A Network Meta-Analysis. BMC Endocr. Disord., 24.","DOI":"10.1186\/s12902-024-01805-z"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"(2023). The Lancet Diabetes: A Defining Disease of the 21st Century. Lancet, 401, 2087.","DOI":"10.1016\/S0140-6736(23)01296-5"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e2004","DOI":"10.1002\/hsr2.2004","article-title":"Diabetes Mellitus, the Fastest Growing Global Public Health Concern: Early Detection Should Be Focused","volume":"7","author":"Hossain","year":"2024","journal-title":"Health Sci. Rep."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/S0140-6736(17)30058-2","article-title":"Type 2 Diabetes","volume":"389","author":"Chatterjee","year":"2017","journal-title":"Lancet"},{"key":"ref_6","first-page":"e51151","article-title":"Novel Therapies in Diabetes: A Comprehensive Narrative Review of GLP-1 Receptor Agonists, SGLT2 Inhibitors, and Beyond","volume":"15","author":"Olanrewaju","year":"2023","journal-title":"Cureus"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Asmat, K., Dhamani, K., Gul, R., and Froelicher, E.S. (2022). The Effectiveness of Patient-Centered Care vs. Usual Care in Type 2 Diabetes Self-Management: A Systematic Review and Meta-Analysis. Front. Public Health, 10.","DOI":"10.3389\/fpubh.2022.994766"},{"key":"ref_8","first-page":"E32","article-title":"Half of Patients with Type 2 Diabetes Mellitus Are at Very High Cardiovascular Risk According to the ESC\/EASD: Data from a Large Mediterranean Population","volume":"28","author":"Mauricio","year":"2021","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1161\/CIR.0000000000001186","article-title":"A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1016\/j.ekir.2024.05.033","article-title":"Combination of Cardiovascular, Kidney, and Metabolic Diseases in a Syndrome Named Cardiovascular-Kidney-Metabolic, with New Risk Prediction Equations","volume":"9","author":"Massy","year":"2024","journal-title":"Kidney Int. Rep."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Mutruc, V., Bologa, C., \u0218orodoc, V., Ceasovschih, A., Mor\u0103ra\u0219u, B.C., \u0218orodoc, L., Catar, O.E., and Lionte, C. (2025). Cardiovascular\u2013Kidney\u2013Metabolic Syndrome: A New Paradigm in Clinical Medicine or Going Back to Basics?. J. Clin. Med., 14.","DOI":"10.3390\/jcm14082833"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Gajjar, A., Raju, A.K., Gajjar, A., Menon, M., Shah, S.A.Y., Dani, S., and Weinberg, A. (2025). SGLT2 Inhibitors and GLP-1 Receptor Agonists in Cardiovascular-Kidney-Metabolic Syndrome. Biomedicines, 13.","DOI":"10.3390\/biomedicines13081924"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1080\/14656566.2025.2504702","article-title":"The Contemporary Landscape of Cardiovascular Optimization in Type 2 Diabetes: Overcoming Barriers to Evidence-Based Use of Newer Antihyperglycemic Agents","volume":"26","author":"Malas","year":"2025","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11892-025-01601-6","article-title":"Review of Health Care Professional-Delivered Behavioral Interventions for Youth with Type 1 Diabetes","volume":"25","author":"Straton","year":"2025","journal-title":"Curr. Diab. Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40520-025-03240-z","article-title":"Prevalence of Polypharmacy among Older Adults with Diabetes: A Systematic Review and Meta-Analysis","volume":"37","author":"Satapathy","year":"2025","journal-title":"Aging Clin. Exp. Res."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Atak Tel, B.M., Aktas, G., Bilgin, S., Baltaci, S.B., and Taslamacioglu Duman, T. (2023). Control Level of Type 2 Diabetes Mellitus in the Elderly Is Associated with Polypharmacy, Accompanied Comorbidities, and Various Increased Risks According to the Beers Criteria. Diagnostics, 13.","DOI":"10.3390\/diagnostics13223433"},{"key":"ref_17","unstructured":"(2025). Summary of Revisions: Standards of Care in Diabetes-2025. Diabetes Care, 48, S6\u2013S13."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Castro Conde, A., Marzal Mart\u00edn, D., Campuzano Ruiz, R., Fern\u00e1ndez Olmo, M.R., Morillas Ari\u00f1o, C., G\u00f3mez Doblas, J.J., Gorriz Teruel, J.L., Maz\u00f3n Ramos, P., Garc\u00eda-Moll Marimon, X., and Soler Romeo, M.J. (2023). Comprehensive Cardiovascular and Renal Protection in Patients with Type 2 Diabetes. J. Clin. Med., 12.","DOI":"10.3390\/jcm12123925"},{"key":"ref_19","first-page":"1","article-title":"Current Treatment for Diabetes: A Holistic Approach","volume":"2025","author":"Mourelatou","year":"2025","journal-title":"Hormones"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s00125-025-06581-6","article-title":"Pharmacological Therapies for Type 2 Diabetes: Future Approaches","volume":"69","author":"Bailey","year":"2025","journal-title":"Diabetologia"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"100082","DOI":"10.1016\/j.pharmr.2025.100082","article-title":"Modern Antidiabetic Therapy by Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Receptor Agonists, and Dipeptidyl Peptidase 4 Inhibitors against Cardiovascular Diseases","volume":"77","author":"Steven","year":"2025","journal-title":"Pharmacol. Rev."},{"key":"ref_22","first-page":"e43697","article-title":"Advances in the Management of Diabetes Mellitus: A Focus on Personalized Medicine","volume":"15","author":"Sugandh","year":"2023","journal-title":"Cureus"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1007\/s41999-025-01168-1","article-title":"Challenges, Current Innovations, and Opportunities for Managing Type 2 Diabetes in Frail Older Adults: A Position Paper of the European Geriatric Medicine Society (EuGMS)\u2014Special Interest Group in Diabetes","volume":"16","author":"Boccardi","year":"2025","journal-title":"Eur. Geriatr. Med."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Uddin, S., Sanchez Machado, M., Alshahrouri, B., Echeverri, J.I., Rico, M.C., Rao, A.D., Ruchalski, C., and Barrero, C.A. (2025). Empowering Pharmacists in Type 2 Diabetes Care: Opportunities for Prevention, Counseling, and Therapeutic Optimization. J. Clin. Med., 14.","DOI":"10.3390\/jcm14113822"},{"key":"ref_25","first-page":"2000","article-title":"Clinical Pharmacists\u2019 Interventions in the Management of Type 2 Diabetes Mellitus: A Systematic Review","volume":"18","author":"Pousinho","year":"2020","journal-title":"Pharm. Pract."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes","volume":"44","author":"Marx","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Weinberg Sibony, R., Segev, O., Dor, S., and Raz, I. (2023). Drug Therapies for Diabetes. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242417147"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1001\/jama.2019.13772","article-title":"Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients with Type 2 Diabetes: The CAROLINA Randomized Clinical Trial","volume":"322","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jama.2018.18269","article-title":"Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults with Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.2337\/dci22-0034","article-title":"Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"45","author":"Davies","year":"2022","journal-title":"Diabetes Care"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.numecd.2016.01.001","article-title":"Dipeptidyl Peptidase-4 Inhibition in Chronic Kidney Disease and Potential for Protection against Diabetes-Related Renal Injury","volume":"26","author":"Penno","year":"2016","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Kawanami, D., Takashi, Y., Takahashi, H., Motonaga, R., and Tanabe, M. (2021). Renoprotective Effects of DPP-4 Inhibitors. Antioxidants, 10.","DOI":"10.3390\/antiox10020246"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2337\/dc10-1771","article-title":"Use of Dipeptidyl Peptidase-4 Inhibitors and the Reporting of Infections: A Disproportionality Analysis in the World Health Organization VigiBase","volume":"34","author":"Willemen","year":"2011","journal-title":"Diabetes Care"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/pds.4560","article-title":"Association between Dipeptidyl Peptidase-4 Inhibitors and Urinary Tract Infection in Elderly Patients: A Retrospective Cohort Study","volume":"27","author":"Imatoh","year":"2018","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_37","unstructured":"(2026, January 11). FDA Drug Safety Communication: FDA Warns That DPP-4 Inhibitors for Type 2 Diabetes May Cause Severe Joint Pain, Available online: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-warns-dpp-4-inhibitors-type-2-diabetes-may-cause-severe-joint-pain."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"R211","DOI":"10.1530\/EJE-19-0566","article-title":"Management of endocrine disease: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?","volume":"181","author":"Nauck","year":"2019","journal-title":"Eur. J. Endocrinol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"101102","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes\u2014State-of-the-Art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol. Metab."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients with Type 2 Diabetes (SURPASS-1): A Double-Blind, Randomised, Phase 3 Trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1056\/NEJMe2109957","article-title":"Breaking New Ground with Incretin Therapy in Diabetes","volume":"385","author":"Tuttle","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes","volume":"385","author":"Davies","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like Peptide-1 Receptor: Mechanisms and Advances in Therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12933-025-02608-9","article-title":"Glucagon-like Peptide-1 Receptor Agonists (GLP-1RAs) and Cardiometabolic Protection: Historical Development and Future Challenges","volume":"24","author":"Westermeier","year":"2025","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"103363","DOI":"10.1016\/j.eclinm.2025.103363","article-title":"The Expanding Role of GLP-1 Receptor Agonists: A Narrative Review of Current Evidence and Future Directions","volume":"86","author":"Moiz","year":"2025","journal-title":"EClinicalMedicine"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13098-025-01623-w","article-title":"GLP-1-Based Therapies for Type 2 Diabetes: From Single, Dual and Triple Agonists to Endogenous GLP-1 Production and L-Cell Differentiation","volume":"17","author":"Movahednasab","year":"2025","journal-title":"Diabetol. Metab. Syndr."},{"key":"ref_47","unstructured":"Collins, L., and Costello, R.A. (2024). Glucagon-Like Peptide-1 Receptor Agonists, StatPearls."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"102782","DOI":"10.1016\/j.eclinm.2024.102782","article-title":"GLP-1 Single, Dual, and Triple Receptor Agonists for Treating Type 2 Diabetes and Obesity: A Narrative Review","volume":"75","author":"Alfaris","year":"2024","journal-title":"EClinicalMedicine"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/dom.13955","article-title":"Semaglutide (SUSTAIN and PIONEER) Reduces Cardiovascular Events in Type 2 Diabetes across Varying Cardiovascular Risk","volume":"22","author":"Husain","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.coph.2020.08.018","article-title":"Renal Protection with Glucagon-like Peptide-1 Receptor Agonists","volume":"54","author":"Vitale","year":"2020","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Bulum, T. (2022). Nephroprotective Properties of the Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) Receptor Agonists. Biomedicines, 10.","DOI":"10.3390\/biomedicines10102586"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"386","DOI":"10.4093\/dmj.2025.0220","article-title":"SGLT2 Inhibitors and GLP-1 Receptor Agonists in Diabetic Kidney Disease: Evolving Evidence and Clinical Application","volume":"49","author":"Bae","year":"2025","journal-title":"Diabetes Metab. J."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.nefro.2022.07.008","article-title":"Glucagon-like Peptide 1(GLP-1) Receptor Agonists in the Management of the Patient with Type 2diabetes Mellitus and Chronic Kidney Disease: An Approach for the Nephrologist","volume":"43","author":"Cases","year":"2023","journal-title":"Nefrologia"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jagp.2023.08.010","article-title":"The Antidepressant Effects of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis","volume":"32","author":"Chen","year":"2024","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-Weekly Semaglutide in Adults with Overweight or Obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/dom.14863","article-title":"Semaglutide for the Treatment of Overweight and Obesity: A Review","volume":"25","author":"Bergmann","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/dom.14890","article-title":"Semaglutide Improves Cardiometabolic Risk Factors in Adults with Overweight or Obesity: STEP 1 and 4 Exploratory Analyses","volume":"25","author":"Kosiborod","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"105782","DOI":"10.1016\/j.phrs.2021.105782","article-title":"Anti-Diabetic Drugs and Weight Loss in Patients with Type 2 Diabetes","volume":"171","author":"Lazzaroni","year":"2021","journal-title":"Pharmacol. Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"103212","DOI":"10.1016\/j.dsx.2025.103212","article-title":"Comparative Efficacy and Safety of Semaglutide 2.4 Mg and Tirzepatide 5\u201315 Mg in Obesity with or without Type 2 Diabetes: A Systematic Review of Phase 3 Clinical Trials","volume":"19","author":"Singh","year":"2025","journal-title":"Diabetes Metab. Syndr. Clin. Res. Rev."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A Randomized, Controlled Trial of 3.0 Mg of Liraglutide in Weight Management","volume":"373","author":"Astrup","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1111\/dom.12986","article-title":"Efficacy and Safety of Lixisenatide in Patients with Type 2 Diabetes and Renal Impairment","volume":"19","author":"Hanefeld","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1365-2125.2007.02890.x","article-title":"Effect of Renal Impairment on the Pharmacokinetics of Exenatide","volume":"64","author":"Linnebjerg","year":"2007","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_63","unstructured":"(2026, January 11). GI Adverse Effects of Glucagon-Like Peptide-1 Receptor Agonists. Available online: https:\/\/www.uspharmacist.com\/article\/gi-adverse-effects-of-glucagonlike-peptide1-receptor-agonists."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Aldhaleei, W.A., Abegaz, T.M., and Bhagavathula, A.S. (2024). Glucagon-like Peptide-1 Receptor Agonists Associated Gastrointestinal Adverse Events: A Cross-Sectional Analysis of the National Institutes of Health All of Us Cohort. Pharmaceuticals, 17.","DOI":"10.3390\/ph17020199"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1053\/j.gastro.2025.06.003","article-title":"Glucagon-Like Peptide-1 Receptor Agonists and Gastrointestinal Adverse Events: A Systematic Review and Meta-Analysis","volume":"169","author":"Chiang","year":"2025","journal-title":"Gastroenterology"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/00185787221125724","article-title":"Tirzepatide","volume":"58","author":"Baker","year":"2024","journal-title":"Hosp. Pharm."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s00125-022-05715-4","article-title":"Management of Type 2 Diabetes with the Dual GIP\/GLP-1 Receptor Agonist Tirzepatide: A Systematic Review and Meta-Analysis","volume":"65","author":"Karagiannis","year":"2022","journal-title":"Diabetologia"},{"key":"ref_68","first-page":"618","article-title":"Tirzepatide (Mounjaro\u00ae): A GIP\/GLP-1 Receptor Dual Agonist for the Treatment of Type 2 Diabetes","volume":"80","author":"Scheen","year":"2025","journal-title":"Rev. Med. Liege"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Forzano, I., Varzideh, F., Avvisato, R., Jankauskas, S.S., Mone, P., and Santulli, G. (2022). Tirzepatide: A Systematic Update. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232314631"},{"key":"ref_70","first-page":"671","article-title":"The Modern Role of Basal Insulin in Advancing Therapy in People with Type 2 Diabetes","volume":"48","author":"Bolli","year":"2025","journal-title":"Diabetes Care"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S2213-8587(22)00243-1","article-title":"Effects of Tirzepatide versus Insulin Glargine on Kidney Outcomes in Type 2 Diabetes in the SURPASS-4 Trial: Post-Hoc Analysis of an Open-Label, Randomised, Phase 3 Trial","volume":"10","author":"Heerspink","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/dom.15318","article-title":"Tirzepatide Reduces the Predicted Risk of Atherosclerotic Cardiovascular Disease and Improves Cardiometabolic Risk Factors in Adults with Obesity or Overweight: SURMOUNT-1 Post Hoc Analysis","volume":"26","author":"Hankosky","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/imj.16625","article-title":"Treatment of Obesity: Will Incretin Agonists Make Bariatric Surgery a Thing of the Past?","volume":"55","author":"Lah","year":"2025","journal-title":"Intern. Med. J."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1111\/dom.16372","article-title":"Association of Tirzepatide with Glycaemic Control and Weight Loss in a Real World Cohort of Patients with Type 2 Diabetes from the United States","volume":"27","author":"Mody","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1111\/dom.16554","article-title":"Weight Reduction over Time in Tirzepatide-treated Participants by Early Weight Loss Response: Post Hoc Analysis in SURMOUNT-1","volume":"27","author":"Ard","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s11739-023-03237-4","article-title":"Pharmacotherapy for Chronic Obesity Management: A Look into the Future","volume":"18","author":"Yang","year":"2023","journal-title":"Intern. Emerg. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1001\/jamainternmed.2024.2525","article-title":"Semaglutide vs Tirzepatide for Weight Loss in Adults with Overweight or Obesity","volume":"184","author":"Rodriguez","year":"2024","journal-title":"JAMA Intern. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"7385","DOI":"10.1111\/dom.70143","article-title":"Tirzepatide and the 10-Year Predicted Risk of Cardiovascular Disease and Type 2 Diabetes in Adults with Obesity and Prediabetes: A Post Hoc Analysis from the Three-Year SURMOUNT-1 Trial","volume":"27","author":"Hankosky","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Fonseca-Correa, J.I., and Correa-Rotter, R. (2021). Sodium-Glucose Cotransporter 2 Inhibitors Mechanisms of Action: A Review. Front. Med., 8.","DOI":"10.3389\/fmed.2021.777861"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Chan, J.C.H., Chan, M.C.Y., Muscoli, S., Vidal-Perez, R., Chan, J.C.H., and Chan, M.C.Y. (2023). SGLT2 Inhibitors: The Next Blockbuster Multifaceted Drug?. Medicina, 59.","DOI":"10.3390\/medicina59020388"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in Heart Failure with a Preserved Ejection Fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1161\/CIRCULATIONAHA.118.034222","article-title":"Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus","volume":"138","author":"Figtree","year":"2018","journal-title":"Circulation"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/dom.12829","article-title":"Rationale, Design and Baseline Characteristics of the CANagliflozin CardioVascular Assessment Study\u2013Renal (CANVAS-R): A Randomized, Placebo-Controlled Trial","volume":"19","author":"Neal","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ahj.2018.01.012","article-title":"The Design and Rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)\u2013TIMI 58 Trial","volume":"200","author":"Wiviott","year":"2018","journal-title":"Am. Heart J."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"The EMPA-KIDNEY Collaborative Group, Herrington, W.G., Staplin, N., Wanner, C., Green, J.B., Hauske, S.J., Emberson, J., Preiss, D., Judge, P., and Mayne, K.J. (2023). Empagliflozin in Patients with Chronic Kidney Disease. N. Engl. J. Med., 388, 117\u2013127.","DOI":"10.1056\/NEJMoa2204233"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in Patients with Chronic Kidney Disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3949\/ccjm.92a.24071","article-title":"Managing the Side Effects of Sodium-Glucose Cotransporter-2 Inhibitors","volume":"92","author":"Kodur","year":"2025","journal-title":"Cleve. Clin. J. Med."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Al Assaf, S., Zelko, R., and Hanko, B. (2022). The Effect of Interventions Led by Community Pharmacists in Primary Care for Adults with Type 2 Diabetes Mellitus on Therapeutic Adherence and HbA1c Levels: A Systematic Review. Int. J. Environ. Res. Public Health, 19.","DOI":"10.3390\/ijerph19106188"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1080\/21556660.2018.1535437","article-title":"Physician-Community Pharmacist Collaborative Care in Diabetes Management: A Pilot Study","volume":"7","author":"Mouhtadi","year":"2018","journal-title":"J. Drug Assess."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"745","DOI":"10.3122\/jabfm.2020.05.200044","article-title":"Impact of Physician-Pharmacist Collaboration on Diabetes Outcomes and Health Care Use","volume":"33","author":"Norton","year":"2020","journal-title":"J. Am. Board Fam. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1007\/s44197-024-00244-2","article-title":"Sustainable Implementation of Physician-Pharmacist Collaborative Clinics for Diabetes Management in Primary Healthcare Centers: A Qualitative Study","volume":"14","author":"Xiao","year":"2024","journal-title":"J. Epidemiol. Glob. Health"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1345\/aph.1S079","article-title":"Pharmacist-Physician Collaboration for Diabetes Care: The Diabetes Initiative Program","volume":"47","author":"Farland","year":"2013","journal-title":"Ann. Pharmacother."},{"key":"ref_96","first-page":"32","article-title":"Analysis of Glycemic Control of a Pharmacist-Led Medication Management Program in Patients with Type 2 Diabetes","volume":"22","author":"Ko","year":"2016","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.2147\/DMSO.S342936","article-title":"Pharmacist-Managed Diabetes Programs: Improving Treatment Adherence and Patient Outcomes","volume":"15","author":"Orabone","year":"2022","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Coutureau, C., Slimano, F., Mongaret, C., and Kanagaratnam, L. (2022). Impact of Pharmacists-Led Interventions in Primary Care for Adults with Type 2 Diabetes on HbA1c Levels: A Systematic Review and Meta-Analysis. Int. J. Environ. Res. Public Health, 19.","DOI":"10.3390\/ijerph19063156"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1177\/1060028017733272","article-title":"Effective Interventions for Diabetes Patients by Community Pharmacists: A Meta-Analysis of Pharmaceutical Care Components","volume":"52","author":"Deters","year":"2018","journal-title":"Ann. Pharmacother."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.sapharm.2018.09.021","article-title":"Pharmacy-Led Interventions to Improve Medication Adherence among Adults with Diabetes: A Systematic Review and Meta-Analysis","volume":"15","author":"Presley","year":"2019","journal-title":"Res. Soc. Adm. Pharm."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.2147\/PPA.S180256","article-title":"Effectiveness of Pharmacist-Led Educational Interventions on Self-Care Activities and Glycemic Control of Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis","volume":"12","author":"Bukhsh","year":"2018","journal-title":"Patient Prefer. Adherence"},{"key":"ref_102","first-page":"493","article-title":"Pharmacist Interventions in the Management of Type 2 Diabetes Mellitus: A Systematic Review of Randomized Controlled Trials","volume":"22","author":"Pousinho","year":"2016","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"van Eikenhorst, L., Taxis, K., van Dijk, L., and de Gier, H. (2017). Pharmacist-Led Self-Management Interventions to Improve Diabetes Outcomes. A Systematic Literature Review and Meta-Analysis. Front. Pharmacol., 8.","DOI":"10.3389\/fphar.2017.00891"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Blanco-Vega, D.D., Reyes-L\u00f3pez, A., Vargas-Neri, J.L., and Osnaya-Valencia, F.I. (2024). Effects of Pharmacist-Led Interventions Regarding Adult Patients with Type 2 Diabetes Mellitus in Mexico: A Systematic Review. Pharmacy, 12.","DOI":"10.3390\/pharmacy12050148"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s11096-020-01084-3","article-title":"A Systematic Review of Pharmacist Input to Metabolic Syndrome Screening, Management and Prevention","volume":"42","author":"Stewart","year":"2020","journal-title":"Int. J. Clin. Pharm."},{"key":"ref_106","unstructured":"(2026, January 11). Pharmacist Toolkit Tier 2: Screen, Test, Refer, and Enroll Patients, Available online: https:\/\/www.cdc.gov\/diabetes-prevention\/hcp\/pharmacists-toolkit\/tier-2-screen-refer-enroll-patients.html."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/fampra\/cmac110","article-title":"Evaluation of a Pharmacist\u2019s Impact on the Use of Glucagon-like Peptide-1 Receptor Agonists for Weight Management in a Family Medicine Setting","volume":"40","author":"Crocetta","year":"2023","journal-title":"Fam. Pract."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1007\/s12325-017-0491-1","article-title":"The Role of the Pharmacist in Managing Type 2 Diabetes with Glucagon-Like Peptide-1 Receptor Agonists as Add-On Therapy","volume":"34","author":"Meece","year":"2017","journal-title":"Adv. Ther."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s11096-025-01863-w","article-title":"Pharmacist-Led Deprescribing of Cardiovascular and Diabetes Medication within a Clinical Medication Review: The LeMON Study (Less Medicines in Older Patients in the Netherlands), a Cluster Randomized Controlled Trial","volume":"47","author":"Abou","year":"2025","journal-title":"Int. J. Clin. Pharm."},{"key":"ref_110","first-page":"927","article-title":"Evaluation of a Pharmacist-Managed Antidiabetic Deprescribing Program in an Integrated Health Care System","volume":"25","author":"Hui","year":"2019","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Torres-Novellas, B., Rius, P., Figueiredo-Escrib\u00e1, C., Mari\u00f1o, E.L., and Modamio, P. (2024). Drug-Related Problems Detected in Complex Chronic Patients by Community Pharmacists of Catalonia: Perception of the Person-Centred Approach Necessity. Healthcare, 12.","DOI":"10.3390\/healthcare12020240"},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Schindler, E., Hohmann, C., and Culmsee, C. (2020). Medication Review by Community Pharmacists for Type 2 Diabetes Patients in Routine Care: Results of the DIATHEM-Study. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.01176"},{"key":"ref_113","unstructured":"(2026, January 11). Community Pharmacy-Driven Diabetes Intervention Leads Value-Based Care. Available online: https:\/\/www.pharmacytimes.com\/view\/community-pharmacy-driven-diabetes-intervention-leads-value-based-care."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Khan, Y.H., Alzarea, A.I., Alotaibi, N.H., Alatawi, A.D., Khokhar, A., Alanazi, A.S., Butt, M.H., Alshehri, A.A., Alshehri, S., and Alatawi, Y. (2022). Evaluation of Impact of a Pharmacist-Led Educational Campaign on Disease Knowledge, Practices and Medication Adherence for Type-2 Diabetic Patients: A Prospective Pre- and Post-Analysis. Int. J. Environ. Res. Public Health, 19.","DOI":"10.3390\/ijerph191610060"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1177\/26350106251361368","article-title":"Evaluating Pharmacist-Driven Interventions in Multidisciplinary Diabetes Care: A Quasi-Experimental Study","volume":"51","author":"Pao","year":"2025","journal-title":"Sci. Diabetes Self Manag. Care"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Mascolo, A., Di Napoli, R., Balzano, N., Cappetta, D., Urbanek, K., De Angelis, A., Scisciola, L., Di Meo, I., Sullo, M.G., and Rafaniello, C. (2022). Safety Profile of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A Brief Summary. Front. Cardiovasc. Med., 9.","DOI":"10.3389\/fcvm.2022.1010693"},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Confederat, L.G., Dragostin, O.M., and Condurache, M.I. (2025). SGLT2 Inhibitors and the Risk of Urogenital Infections: A Concise Review. J. Clin. Med., 14.","DOI":"10.3390\/jcm14061960"},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Menditto, E., Aznar-Lou, I., Funabashi, A., Ito, H., Maeda, M., Hasegawa, Y., Tsukioka, R., and Onda, M. (2025). Evaluation of a Community Pharmacist-Led Intervention Program for Early Detection of Gastrointestinal Adverse Events of Dipeptidyl Peptidase-4 Inhibitors: A Multicenter, Non-Randomized Comparative Study. Pharmacy, 13.","DOI":"10.3390\/pharmacy13050119"},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"White, A., Thompson, E.L., Kim, S., Osei, J.A., Fulda, K.G., and Xiao, Y. (2025). Enhancing the Role of Community Pharmacists in Medication Safety: A Qualitative Study of Voices from the Frontline. Pharmacy, 13.","DOI":"10.3390\/pharmacy13040094"},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Ali, Z.Z., Skouteris, H., Pirotta, S., Hussainy, S.Y., Low, Y.L., Mazza, D., and Assifi, A.R. (2024). Interventions to Expand Community Pharmacists\u2019 Scope of Practice. Pharmacy, 12.","DOI":"10.3390\/pharmacy12030095"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"e193","DOI":"10.5210\/ojphi.v8i2.6802","article-title":"Why Do We Need Pharmacists in Pharmacovigilance Systems?","volume":"8","author":"Toklu","year":"2016","journal-title":"Online J. Public Health Inform."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"e224","DOI":"10.1016\/j.japh.2020.07.025","article-title":"Pharmacist-Led Motivational Interviewing for Diabetes Medication Adherence in a Worksite Wellness Program","volume":"60","author":"Ekong","year":"2020","journal-title":"J. Am. Pharm. Assoc."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.sapharm.2020.03.026","article-title":"Effectiveness of a Pharmacist-Led Structured Group-Based Intervention in Improving Medication Adherence and Glycaemic Control among Type 2 Diabetes Mellitus Patients: A Randomized Controlled Trial","volume":"17","author":"Ting","year":"2021","journal-title":"Res. Soc. Adm. Pharm."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2147\/PPA.S394201","article-title":"Effect of Pharmacist-Led Interventions on Medication Adherence and Glycemic Control in Type 2 Diabetic Patients: A Study from the Chinese Population","volume":"17","author":"Wu","year":"2023","journal-title":"Patient Prefer. Adherence"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2147\/JMDH.S494584","article-title":"Pharmacist-Led Digital Health Interventions for Patients with Diabetes: A Systematic Review","volume":"18","author":"Christy","year":"2025","journal-title":"J. Multidiscip. Healthc."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.sapharm.2025.10.002","article-title":"A Digital Health-Supported Community Pharmacy-Based Lifestyle Intervention Program for Overweight or Obese Adults with Prediabetes, the PRediabetes Intervention, Management and Evaluation (PRIME) Program: A Cluster Randomized Controlled Trial","volume":"22","author":"Teoh","year":"2025","journal-title":"Res. Soc. Adm. Pharm."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.nutres.2025.04.005","article-title":"A Digital Health-Supported Prediabetes Intervention, Management and Evaluation (PRIME) Program Improves Healthy Eating Index Score: A Cluster Randomized Controlled Trial","volume":"138","author":"Ng","year":"2025","journal-title":"Nutr. Res."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"9","DOI":"10.24926\/iip.v15i1.6081","article-title":"Clinical and Financial Outcomes of a Pilot Pharmacist-Led Continuous Glucose Monitoring Clinic","volume":"15","author":"Ballard","year":"2024","journal-title":"Innov. Pharm."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"102078","DOI":"10.1016\/j.japh.2024.102078","article-title":"Evaluation of a Community-Based Pharmacy Resident-Led Continuous Glucose Monitoring Program within a Family Medicine Clinic","volume":"64","author":"Miller","year":"2024","journal-title":"J. Am. Pharm. Assoc."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/j.japh.2023.07.010","article-title":"Pharmacist-Driven Continuous Glucose Monitoring in Community and Ambulatory Care Pharmacy Practice: A Scoping Review","volume":"63","author":"Vascimini","year":"2023","journal-title":"J. Am. Pharm. Assoc."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1007\/s11096-018-0696-7","article-title":"PCNE Definition of Medication Review: Reaching Agreement","volume":"40","author":"Hersberger","year":"2018","journal-title":"Int. J. Clin. Pharm."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.pcd.2019.12.007","article-title":"The Impact of Pharmacist Care on Diabetes Outcomes in Primary Care Settings: An Umbrella Review of Published Systematic Reviews","volume":"14","author":"Abdulrhim","year":"2020","journal-title":"Prim. Care Diabetes"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1111\/jgs.19463","article-title":"Impact of Comprehensive Medication Reviews on Medicare Beneficiaries with Type 2 Diabetes","volume":"73","author":"Shen","year":"2025","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Barrea, L., Vetrani, C., Verde, L., Frias-Toral, E., Ceriani, F., Cernea, S., Docimo, A., Graziadio, C., Tripathy, D., and Savastano, S. (2023). Comprehensive Approach to Medical Nutrition Therapy in Patients with Type 2 Diabetes Mellitus: From Diet to Bioactive Compounds. Antioxidants, 12.","DOI":"10.3390\/antiox12040904"},{"key":"ref_135","first-page":"1","article-title":"Type 2 Diabetes Mellitus and the Gut Microbiota: Charting New Territory for Sodium-Glucose Co-Transporter 2 Inhibitors","volume":"8","author":"Stepanova","year":"2024","journal-title":"Eurasian J. Med. Oncol."},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Minari, T.P., T\u00e1cito, L.H.B., Yugar, L.B.T., Ferreira-Melo, S.E., Manzano, C.F., Pires, A.C., Moreno, H., Vilela-Martin, J.F., Cosenso-Martin, L.N., and Yugar-Toledo, J.C. (2023). Nutritional Strategies for the Management of Type 2 Diabetes Mellitus: A Narrative Review. Nutrients, 15.","DOI":"10.3390\/nu15245096"},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Wang, X.F., Chen, X., Tang, Y., Wu, J.M., Qin, D.L., Yu, L., Yu, C.L., Zhou, X.G., and Wu, A.G. (2022). The Therapeutic Potential of Plant Polysaccharides in Metabolic Diseases. Pharmaceuticals, 15.","DOI":"10.3390\/ph15111329"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"103336","DOI":"10.1016\/j.jbi.2019.103336","article-title":"PharmActa: Personalized Pharmaceutical Care EHealth Platform for Patients and Pharmacists","volume":"100","author":"Spanakis","year":"2019","journal-title":"J. Biomed. Inform."},{"key":"ref_139","first-page":"100567","article-title":"E-Health Applications for Outpatient Professional Pharmaceutical Care Services: A Scoping Review","volume":"17","author":"Agudelo","year":"2025","journal-title":"Explor. Res. Clin. Soc. Pharm."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"102106","DOI":"10.1016\/j.japh.2024.102106","article-title":"Assessment of a Community Pharmacist Remote Monitoring Service in Patients Using Continuous Glucose Monitors","volume":"64","author":"Beldon","year":"2024","journal-title":"J. Am. Pharm. Assoc."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"e67014","DOI":"10.2196\/67014","article-title":"Impact of Pharmacist-Led Continuous Glucose Monitoring on Clinical Outcomes in People with Type 2 Diabetes in Primary Care: Protocol for a Prospective Cohort Study","volume":"14","author":"Cowart","year":"2025","journal-title":"JMIR Res. Protoc."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.japh.2022.08.003","article-title":"Exploring Barriers and Facilitators to Pharmacist-Provided Diabetes Self-Management Education and Support","volume":"63","author":"Gawlik","year":"2023","journal-title":"J. Am. Pharm. Assoc."},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Kroenert, A.C., and Bertsche, T. (2024). Implementation, Barriers, Solving Strategies and Future Perspectives of Reimbursed Community Pharmacy Services-a Nationwide Survey for Community Pharmacies in Germany. BMC Health Serv. Res., 24.","DOI":"10.1186\/s12913-024-11745-y"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1111\/dom.13830","article-title":"Treatment Patterns and Associated Factors in 14 668 People with Type 2 Diabetes Initiating a Second-Line Therapy: Results from the Global DISCOVER Study Programme","volume":"21","author":"Nicolucci","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"E214182","DOI":"10.1001\/jamahealthforum.2021.4182","article-title":"Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1 Receptor Agonist Use among Patients with Diabetes in the US","volume":"2","author":"Eberly","year":"2021","journal-title":"JAMA Health Forum"},{"key":"ref_146","first-page":"100759","article-title":"Race and Ethnicity and Pharmacy Dispensing of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes","volume":"34","author":"Rodriguez","year":"2024","journal-title":"Lancet Reg. Health Am."},{"key":"ref_147","first-page":"100111","article-title":"Racial\/Ethnic and Socioeconomic Disparities in the Use of Newer Diabetes Medications in the Look AHEAD Study","volume":"6","author":"Elhussein","year":"2022","journal-title":"Lancet Reg. Health Am."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1001\/jama.2025.24288","article-title":"World Health Organization Guideline on the Use and Indications of Glucagon-Like Peptide-1 Therapies for the Treatment of Obesity in Adults","volume":"335","author":"Celletti","year":"2025","journal-title":"JAMA"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"659","DOI":"10.12688\/f1000research.122170.1","article-title":"Knowledge and Practice of Community Pharmacists towards SGLT2 Inhibitors","volume":"11","author":"Alqudah","year":"2022","journal-title":"F1000Research"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"198","DOI":"10.5688\/ajpe6461","article-title":"The Benefit of Continuing Professional Development for Continuing Pharmacy Education","volume":"82","author":"Wheeler","year":"2018","journal-title":"Am. J. Pharm. Educ."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s40545-023-00597-2","article-title":"Impact of an Educational Program on Community Pharmacist\u2019s Preparedness to Conduct Pharmacist-Led Diabetes Clinic in Saudi Arabia","volume":"16","author":"Rasheed","year":"2023","journal-title":"J. Pharm. Policy Pract."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1016\/j.sapharm.2025.02.020","article-title":"Empowering Community Pharmacists for Next-Generation Therapeutics: Assessing Knowledge Needs and Implementing Educational Solutions","volume":"Volume 21","author":"Spanakis","year":"2025","journal-title":"Research in Social and Administrative Pharmacy"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.jcjd.2017.08.240","article-title":"Pharmacists Managing People with Diabetes in Primary Care: 10 Years of Experience at the Hamilton Family Health Team","volume":"41","author":"Gagnon","year":"2017","journal-title":"Can. J. Diabetes"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.sapharm.2023.04.124","article-title":"Community Pharmacist-Led Interventions for Patients with Type 2 Diabetes in Low-Income and Middle-Income Countries: A Scoping Review","volume":"19","author":"Cahyaningsih","year":"2023","journal-title":"Res. Soc. Adm. Pharm."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1177\/17151635251362250","article-title":"With Great Power Comes Great Responsibility\u2026.The Role of Pharmacists in Ensuring Health Equity","volume":"158","author":"Paes","year":"2025","journal-title":"Can. Pharm. J. CPJ"},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Kuo, T., Barragan, N.C., and Chen, S. (2024). Leveraging Community Pharmacies to Address Social Needs: A Promising Practice to Improve Healthcare Quality. Pharmacy, 12.","DOI":"10.3390\/pharmacy12050139"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1331\/JAPhA.2014.14063","article-title":"Integrating Pharmacists into Diverse Diabetes Care Teams: Implementation Tactics from Project IMPACT: Diabetes","volume":"54","author":"Watson","year":"2014","journal-title":"J. Am. Pharm. Assoc."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"10-24926","DOI":"10.24926\/iip.v12i1.3591","article-title":"Third-Party Reimbursement of Pharmacist-Led Cardiovascular and Diabetes Preventive Health Services for Workplace Health Initiatives: A Narrative Systematic Review","volume":"12","author":"Tong","year":"2021","journal-title":"Innov. Pharm."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.healthpol.2015.02.007","article-title":"From \u201cRetailers\u201d to Health Care Providers: Transforming the Role of Community Pharmacists in Chronic Disease Management","volume":"119","author":"Mossialos","year":"2015","journal-title":"Health Policy"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/2\/271\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T05:30:58Z","timestamp":1770960658000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/2\/271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":159,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["ph19020271"],"URL":"https:\/\/doi.org\/10.3390\/ph19020271","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]}}}